Thanks for choosing mmm-online.com Sign up for your FREE account now and join the thousands of other healthcare marketing professionals who rely on us for all the latest industry news and innovative ideas for direct and digital strategy. Simply fill out the fields below.

Keep me logged in Forgot your password?

Please wait...

Please wait...

 Patents

Studies show cheaper drugs don't add up to greater use

May 09, 2013

Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
 

Business briefs: Baxter; Eli Lilly; CDHPs and Statins

May 07, 2013

Baxter's Alzheimer's treatment is out of the running; Eli Lilly has upped its layoffs; insured consumers are spending less on healthcare; stains and prostate cancer may have an amicable relationship; doctors aren't screening teens for HIV.
 

Merck throws more staff behind Januvia; overall sales slid for quarter

May 01, 2013

Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise.
 

Patent losses stalk BMS, AZ quarterly results

April 25, 2013

Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets.
 

Business Briefs: AstraZeneca, Amgen, BMS and Merck

April 18, 2013

AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer's advocacy group parents a spin-off.
 

Myriad decision could be a drag on personalized medicine R&D

April 15, 2013

After a skeptical Supreme Court hearing, diagnostics and biopharma patent lawyers are sweating the outcome of Association for Molecular Pathology vs. Myriad Genetics, in which the Court could decide whether or not swatches of genes are patentable.
 

Lilly to boost diabetes sales force amid layoffs in other categories

April 12, 2013

Expiring patents force a sales staff slim-down, but the drug maker emphasizes it is not eliminating its sales force.
 

Success in emerging markets hinges on broad network

April 03, 2013

Execs told Booz & Co researchers that the relationships web in emerging markets needs to be deeper than one-on-one sales pitches.
 

FDA ends year with 39 approvals

January 02, 2013

Eight December approvals helped the agency pass its 2011 total with ease. But it's not all about the pace—the agency needs drugs to approve to keep tallies climbing.
 

Teva says it will cut costs and innovate more

December 12, 2012

The drugmaker told investors Tuesday that generics will remain its standby, but novel therapeutic entities are also in its future.
 

For Forest, one Bystolic test down, six to go

October 29, 2012

Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others.
 

Singulair latest victim of generics onslaught

August 06, 2012

The FDA green-lighted several generic successors to Merck's Singulair. It's one of several newly off-patent meds slated to drive generic utilization, a study shows.
 

Lilly pipeline chokes again as patent expiries loom

July 11, 2012

Lilly's latest R&D disappointment, a schizophrenia drug dubbed mGlu2/3, wasn't a stock killer, but it's yet another in a string of bummers for a firm facing big patent expiries and a thinning stable of pipeline projects.
 

Copaxone sales likely to top out this year, Teva exec says

June 07, 2012

Sales of Teva's MS blockbuster Copaxone are likely to peak this year before giving way as more therapeutic options become available, a Teva exec says.
 

Company news: Elsevier, AstraZeneca, GSK

April 02, 2012

Publisher Elsevier announced Monday that it will increase the number of papers it publishes for the Journal of Diabetes and Its Complications.
 

Novartis slashes 1,960 US sales and marketing jobs amid hypertension franchise implosion

January 13, 2012

Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.
 

Pfizer's post-expiry plan for Lipitor: maximize brand's sales

November 02, 2011

Pfizer said it plans not only to keep Lipitor consumer promotions running past the brand's expiry later this month. It also aims to put an OTC version of the megablockbuster on the market at some point.
 

Brilinta boosts AstraZeneca, but can it carry them over the cliff?

July 21, 2011

The FDA gave the green light to AstraZeneca's Brilinta (ticagrelor) anti-platelet for heart attack prevention, but the brand will carry a black box warning, a Risk Evaluation and Mitigation Strategy requirement and an obligation to educate doctors about possible risks of use in users of high-dose aspirin.
 

Pfizer sales up, as it braces for Lipitor down side

February 01, 2011

Pfizer reported higher fourth-quarter sales, but the world's largest drug maker also revealed more downsizing and R&D cuts as it braces for the expiry of the Lipitor patent later this year.
 

Company news: Takeda and Teva

December 28, 2010

Takeda granted generics firm Teva a license to market authorized copies in the US, starting Aug. 17, 2012, for best-selling diabetes pill Actos, and on Dec. 14, 2012, for Actoplus met (Actos plus metformin).
 

King Pharma resubmits abuse-resistant oxycodone to FDA

December 28, 2010

Two years after receiving a Complete Response letter from FDA about Remoxy, King Pharmaceuticals and Pain Therapeutics announced that they had resubmitted the drug for approval yesterday. A thumbs up or thumbs down from FDA is expected in June.
 

Ruling in FTC-Watson case may sway pay-for-delay debate in Senate

July 19, 2010

A US magistrate judge ruled that the Federal Trade Commission overstepped its authority when the agency tried to pressure a generic drug company to enter into a business deal with a competitor.
 

Watson: FTC abused power in trying to 'engineer' entry of generic Provigil

May 27, 2010

The FTC, which opposes reverse-payment patent settlements but has failed to muffle them via the courts or healthcare reform legislation, is now trying some new tactics: harassment, use of privileged information and attempting to force a pharma company to partner with another firm against its will.
 

No sure fixes for pharma's patent cliff

May 07, 2010

With a spate of high-margin blockbusters going off patent and a lack of replacement products, a Bernstein Research conference explored three potential solutions to the patent cliff.
 

Global drug sales to grow 5%-8% through 2014 despite patent losses, says IMS

April 20, 2010

Global sales of pharmaceuticals will grow at a rate of 5%-8% annually over the next five years, IMS Health forecasts -- even as products with sales of more than $142 billion lose patent protection in top markets, reducing drug spending by $80-$100 billion.
 
  

Web Exclusive

Angelina Jolie's fearless but flawed message

Paul Oestreicher, Ph.D. May 17, 2013

Angelina Jolie's story raises important questions about education, outreach and access—but her nod to holistic treatments is less helpful
 

Podcasts

How to engage even the busiest physicians

March 04, 2013

Sponsored by TRUE Health + Wellness. The increasingly demanding schedules of healthcare professionals continue to narrow the window of opportunity for pharma sales teams, and, as a result, marketers are focusing more on non-personal promotion. However, there's a lot more to it than simply bombarding physicians with brand messages, as Anne Stroup, Managing Director at TRUE Health + Wellness, explains to MM&M's James Chase in this special podcast presentation.
 

2013 Hall of Fame Inductees

An entertaining look at the extraordinary lives and careers of the Medical Advertising Hall of Fame's 2013 inductees: Peter Frishauf, Dorothy Philips and David Labson. Clips produced by JUICE Pharma. 

Slideshows

MAHF 2013: Honors Class

A gallery of images from the 2013 Medical Advertising Hall of Fame induction dinner
 
Popular Topics
Acquisition Adherence Advertising App Approval Centers For Disease Control Clinical Trial Consumer COPD Corporate Reputation Device Diabetes DTC Earnings Elan FDA Generic Generic Drugs iPad Marketing & Communications Mobile Obesity Patients Regulatory Wellness